CytoSorbents Corporation
NASDAQ: CTSO
Working to Save Lives
Through Blood Purification
Cantor Fitzgerald Healthcare Conference
July 13, 2016
Safe Harbor Statement

Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical Inc. and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. It is routine for our internal projections and expectations to change. Although these expectations may change, we are under no obligation to inform you if they do. Actual events or results may differ materially from those contained in the projections or forward-looking statements. The following factors, among others, could cause our actual results to differ materially from those described in a forward-looking statement: our history of losses; potential fluctuations in our quarterly and annual results; competition, inability to achieve regulatory approval for our device, technology systems beyond our control and technology-related defects that could affect the companies’ products or reputation; risks related to adverse business conditions; our dependence on key employees; competition for qualified personnel; the possible unavailability of financing as and if needed; and risks related to protecting our intellectual property rights or potential infringement of the intellectual property rights of third parties. This list is intended to identify only certain of the principal factors that could cause actual results to differ from those discussed in the forward-looking statements. Readers are referred to a discussion of important risk factors detailed in the Company’s Form 10-K filed with the Securities and Exchange Commission on March 9, 2016 and other reports and documents filed from time to time by us, which are available online at [www.sec.gov](http://www.sec.gov).
CytoSorbents is a leader in critical care immunotherapy.

Leading the prevention or treatment of life-threatening inflammation in the ICU and cardiac surgery using CytoSorb® blood purification.
CytoSorbents At a Glance

- NASDAQ-traded (CTSO): Fully-diluted market cap of $140M
- International footprint across two wholly-owned operating subsidiaries
  - CytoSorbents Medical, Inc - Monmouth Junction, NJ
    - Headquarters, ISO 13485 manufacturing, QA/QC, R&D
  - CytoSorbents Europe GmbH: International sales office - Berlin, Germany
    - CytoSorbents Switzerland GmbH
- Flagship product, CytoSorb® is E.U. approved, distributed in 37 countries
- Strategic Partnerships with Fresenius Medical Care and Biocon Ltd
- Strong government support with $17M+ in grants and contracts
- 67 employees and consultants
- Pursuing U.S. approval of CytoSorb® in cardiac surgery via REFRESH I & II
- ~$9M in cash at the end of Q2 2016
- Expecting acceleration of growth outside the U.S. this year with record trailing 12-month sales of $4.9M and gross margins of 62%
Leadership Background

Phillip Chan, MD, PhD – Chief Executive Officer and President
Former Partner at the $80M NJTC Venture Fund, leading life science investments for 5 years. Co-founder of Andrew Technologies, commercializing its HydraSolve™ lipoplasty device in the U.S. MD/PhD from Yale School of Medicine, internal medical residency at the Beth Israel Deaconess Medical Center at Harvard.

Vincent Capponi, MS - Chief Operating Officer
20+ years experience in the medical device, pharmaceutical and imaging fields. Led the first regulatory approval for the heparin flush syringe, used worldwide in hospitals, and managed manufacturing of > 1 million units/week

Kathleen Bloch, MBA, CPA – Chief Financial Officer
20+ years as CFO of private and public companies. Former Laureate Biopharma CFO, a contract biopharmaceutical manufacturer, and CFO of Silverline Windows, a $750M revenue window manufacturing company with 9 manufacturing plants nationally

Robert Bartlett, MD - Chief Medical Officer
World-renowned pioneer of extracorporeal membrane oxygenation therapy (ECMO) – used worldwide in ICUs in refractory lung failure. Former Director of the Surgical Intensive Care Unit at University of Michigan, with extensive experience in cardiothoracic surgery and critical care medicine including the treatment of sepsis

Christian Steiner, MD – Vice President of Sales and Marketing
15+ years experience in sales and marketing of extracorporeal therapy and critical care sales at Teraklin for MARS, the first liver failure dialysis technology, and at Pulsion Medical (hemodynamic monitoring)

Christopher Cramer, MS, MBA – Vice President of Business Development
15+ years experience in business development and commercial experience. Former Senior Director of New Venture Development at Johnson & Johnson, and previously at PwC Consulting
Severe Inflammation: Deadly in the ICU

Millions worldwide admitted to the intensive care unit annually with deadly inflammatory conditions

- In these conditions, little exists to reduce the inflammation and actively help patients get better. Rather, patients often need to be kept alive with machines called “life support”, with the hope that their bodies heal on their own over time.

- Without “active” therapies, patients linger at a cost of $2,000-3,000 a day* with a risk of death of 1 in every 3 patients.

- Critical care costs approximately $80-90 billion in the U.S. alone, or ~1% of the GDP.
Inflammation: Dangerous in Cardiac Surgery

• ~1.5M Open Heart Surgeries performed globally
  • Coronary artery bypass graft surgery
  • Valve repair or replacement
  • Heart or lung transplantation
  • Congenital defect repair
  • Aortic reconstruction

• Complex cardiac surgeries require extended surgical times on the heart-lung machine, resulting in increased destruction of blood cells, production of toxic free hemoglobin, cytokines, and other inflammatory substances that can trigger severe inflammation

• The result is frequently organ dysfunction and failure, particularly cardiovascular, lung and kidney failure
Cytokines Fuel the Fire of Inflammation

- Cytokines are small proteins that normally help stimulate and regulate the immune system and control inflammation.

- Cytokines are a dual edged sword:
  - They are required for proper immune system function.
  - However, in mild to moderate excess, cytokines can cause or exacerbate disease (e.g. autoimmune diseases).

- But cytokines in vast excess, called “cytokine storm” can lead to a massive uncontrolled systemic inflammatory response syndrome (SIRS).
Massive Inflammation Causes Organ Failure

Organ failure occurs when vital organs stop working, causing nearly half of all deaths in the ICU.

Little can be done to prevent or treat it today.
CytoSorb® Removes the Fuel to the Fire

- Targets $20+ billion opportunity in critical care and cardiac surgery
- European Union approved as the only specific cytokine filter for elevated cytokines
- Clinically proven to remove key cytokines in blood of critically-ill patients
- Removes many other inflammatory mediators such as free hemoglobin, bacterial toxins, and bilirubin
- Safe and well-tolerated: In 12,000+ human treatments, most in critically-ill patients and more than 2,000 treatments during open heart surgery

*CytoSorb is not yet approved in the U.S.*
Powerful Blood Purification Technology

The underlying blood purification technology is based on biocompatible, highly porous polymer beads that act like tiny sponges to remove harmful substances from blood.

- Protected by 32 issued US patents and multiple applications pending
- Manufactured at our ISO 13485 certified facility in New Jersey
- One of the highest grade medical sorbents on medical market today

Each bead is about the size of a grain of salt.
CytoSorb® is Plug and Play with Existing Machines

**Easy to Use, No Special Equipment or Training Required**

- Place a temporary dialysis catheter in a major vein.
- Connect the device to a standard dialysis machines found in hospitals worldwide.
- Pump blood out of the body and through the cartridge.
- The polymer beads directly contact blood and remove unwanted or toxic substances.
- “Purified” blood is pumped back into the patient.
- Can treat 70+ total blood volumes per 24 hr treatment.
- Each treatment uses a new cartridge.
Goal: To Prevent or Treat Organ Failure

- Improve Patient Outcome and Survival
- Decrease Costs Of ICU and Patient Care

The Potential to Revolutionize Critical Care Medicine

- Sepsis
- ARDS
- Burn Injury
- Trauma
- Pancreatitis
- Influenza
- Surgical
Case Report: Necrotizing Fasciitis

- A 19-year old man developed a painful infection on his right hand and was rushed to a hospital with high fever and malaise
- Started on broad spectrum antibiotics for a suspected deep infection in the carpal tunnel
- Rapid onset of multi-organ failure with shock, kidney dysfunction and respiratory failure with infection quickly spreading up his arm
- Extensive surgical debridement confirmed beta-hemolytic Streptococcal infection, but condition worsened requiring increasing vasopressors and CRRT for kidney failure
- Failing therapy, CytoSorb was started. After first treatment, blood pressure significantly improved and after two treatments, vasopressors were reduced by 90% and IL-6 declined from 2,300 pg/mL to 36 pg/mL
- Renal function returned after the second CytoSorb treatment and mechanical ventilation was weaned 4 days later
- Patient recovered and amputation of his arm was avoided
$17+ Million in US Government Support

- DARPA awarded $3.8M five year (2012-present) contract as part of “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins
- U.S. Army awarded ~$1.2M SBIR contracts for trauma and burn injury research (2011-present)
- U.S. Air Force funding a 30-patient human pilot study (~$3M) in trauma (2013-present); FDA approved trial
- US Dept of Health and Human Services awarded $0.5M grant (2010) for therapies that can save lives and reduce costs under the QTDP Program
- NIH grant awarded $7M five year (2006-2010) to University of Pittsburgh and Dr. John Kellum to research CytoSorb bead for treatment of sepsis
- NIH/NHLBI awarded $1.7M Phase I & II SBIR contracts to advance HemoDefend purification technology with the goal of improving the quality and safety of blood transfusions (2013- present)
- JPEO-CBD awarded $150K Phase I SBIR for fungal mycotoxin removal
The World Needs CytoSorb®
Key Catalyst #1:

Drive CytoSorb Revenues
CytoSorb® An Excellent Business Model

• Huge market
  Sold to hospitals & critical care doctors. Targets “need to have” life-or-death scenarios

• Little to no competition

• Critical care physicians understand the problem

• Plug and play, high margin, disposable “razorblade”
  Hospital’s existing hemodialysis infrastructure is the “razor”, no new hardware

• Technicians already know how to use the device

• Hospitals in Germany/Austria pay for the device and then receive reimbursement
  Depending on the application and devices used, revenue potential per patient ~$1-5K

• Affordable yet profitable with blended gross margins of 60+, target > 80%

• Highly centralized intensive care units easy for small sales force to access
CytoSorbents’ direct sales force focused on most major university and public hospitals in Germany, Austria and Switzerland. German market alone is $1.0-1.5 billion.
CytoSorb® Distributed in 37 Countries
Geographic Expansion – A Growth Engine

January 2016

<table>
<thead>
<tr>
<th>Contributing to Revenue</th>
<th>Country</th>
<th>Population (M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Germany</td>
<td>81</td>
</tr>
<tr>
<td>2</td>
<td>Austria</td>
<td>9</td>
</tr>
<tr>
<td>3</td>
<td>Switzerland</td>
<td>8</td>
</tr>
<tr>
<td>4</td>
<td>United Kingdom</td>
<td>64</td>
</tr>
<tr>
<td>5</td>
<td>Italy</td>
<td>60</td>
</tr>
<tr>
<td>6</td>
<td>Turkey</td>
<td>75</td>
</tr>
<tr>
<td>7</td>
<td>India</td>
<td>1,200</td>
</tr>
<tr>
<td>8</td>
<td>Sri Lanka</td>
<td>21</td>
</tr>
<tr>
<td>9</td>
<td>Netherlands</td>
<td>17</td>
</tr>
<tr>
<td>10</td>
<td>Romania</td>
<td>20</td>
</tr>
<tr>
<td>11</td>
<td>Ireland</td>
<td>5</td>
</tr>
<tr>
<td>12</td>
<td>Moldova</td>
<td>4</td>
</tr>
<tr>
<td>13</td>
<td>Australia</td>
<td>23</td>
</tr>
<tr>
<td>14</td>
<td>New Zealand</td>
<td>5</td>
</tr>
<tr>
<td>15</td>
<td>Saudi Arabia</td>
<td>29</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1,621</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Not Yet Contributing to Revenue</th>
<th>Country</th>
<th>Population (M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>France</td>
<td>66</td>
</tr>
<tr>
<td>17</td>
<td>Poland</td>
<td>39</td>
</tr>
<tr>
<td>18</td>
<td>Sweden</td>
<td>10</td>
</tr>
<tr>
<td>19</td>
<td>Denmark</td>
<td>6</td>
</tr>
<tr>
<td>20</td>
<td>Norway</td>
<td>5</td>
</tr>
<tr>
<td>21</td>
<td>Finland</td>
<td>5</td>
</tr>
<tr>
<td>22</td>
<td>Russia</td>
<td>144</td>
</tr>
<tr>
<td>23</td>
<td>UAE</td>
<td>9</td>
</tr>
<tr>
<td>24</td>
<td>Qatar</td>
<td>2</td>
</tr>
<tr>
<td>25</td>
<td>Kuwait</td>
<td>3</td>
</tr>
<tr>
<td>26</td>
<td>Oman</td>
<td>4</td>
</tr>
<tr>
<td>27</td>
<td>Bahrain</td>
<td>1</td>
</tr>
<tr>
<td>28</td>
<td>Iraq</td>
<td>33</td>
</tr>
<tr>
<td>29</td>
<td>Jordan</td>
<td>7</td>
</tr>
<tr>
<td>30</td>
<td>Yemen</td>
<td>24</td>
</tr>
<tr>
<td>31</td>
<td>Vietnam</td>
<td>90</td>
</tr>
<tr>
<td>32</td>
<td>Israel</td>
<td>8</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>456</strong></td>
<td></td>
</tr>
</tbody>
</table>

July 2016

<table>
<thead>
<tr>
<th>Contributing to Revenue</th>
<th>Country</th>
<th>Population (M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Germany</td>
<td>81</td>
</tr>
<tr>
<td>2</td>
<td>Austria</td>
<td>9</td>
</tr>
<tr>
<td>3</td>
<td>Switzerland</td>
<td>8</td>
</tr>
<tr>
<td>4</td>
<td>United Kingdom</td>
<td>64</td>
</tr>
<tr>
<td>5</td>
<td>Italy</td>
<td>60</td>
</tr>
<tr>
<td>6</td>
<td>Turkey</td>
<td>75</td>
</tr>
<tr>
<td>7</td>
<td>India</td>
<td>1,200</td>
</tr>
<tr>
<td>8</td>
<td>Sri Lanka</td>
<td>21</td>
</tr>
<tr>
<td>9</td>
<td>Netherlands</td>
<td>17</td>
</tr>
<tr>
<td>10</td>
<td>Romania</td>
<td>20</td>
</tr>
<tr>
<td>11</td>
<td>Ireland</td>
<td>5</td>
</tr>
<tr>
<td>12</td>
<td>Moldova</td>
<td>4</td>
</tr>
<tr>
<td>13</td>
<td>Australia</td>
<td>23</td>
</tr>
<tr>
<td>14</td>
<td>New Zealand</td>
<td>5</td>
</tr>
<tr>
<td>15</td>
<td>Saudi Arabia</td>
<td>29</td>
</tr>
<tr>
<td>16</td>
<td>France</td>
<td>66</td>
</tr>
<tr>
<td>17</td>
<td>Poland</td>
<td>39</td>
</tr>
<tr>
<td>18</td>
<td>Sweden</td>
<td>10</td>
</tr>
<tr>
<td>19</td>
<td>Denmark</td>
<td>6</td>
</tr>
<tr>
<td>20</td>
<td>Norway</td>
<td>5</td>
</tr>
<tr>
<td>21</td>
<td>Finland</td>
<td>5</td>
</tr>
<tr>
<td>22</td>
<td>Russia</td>
<td>144</td>
</tr>
<tr>
<td>23</td>
<td>Spain</td>
<td>46</td>
</tr>
<tr>
<td>24</td>
<td>Portugal</td>
<td>10</td>
</tr>
<tr>
<td>25</td>
<td>Vietnam</td>
<td>90</td>
</tr>
<tr>
<td>26</td>
<td>Hungary</td>
<td>10</td>
</tr>
<tr>
<td>27</td>
<td>Czech Republic</td>
<td>11</td>
</tr>
<tr>
<td>28</td>
<td>Slovakia</td>
<td>5</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>2,068</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Not Yet Contributing to Revenue</th>
<th>Country</th>
<th>Population (M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>29</td>
<td>UAE</td>
<td>9</td>
</tr>
<tr>
<td>30</td>
<td>Qatar</td>
<td>2</td>
</tr>
<tr>
<td>31</td>
<td>Kuwait</td>
<td>3</td>
</tr>
<tr>
<td>32</td>
<td>Oman</td>
<td>4</td>
</tr>
<tr>
<td>33</td>
<td>Bahrain</td>
<td>1</td>
</tr>
<tr>
<td>34</td>
<td>Iraq</td>
<td>33</td>
</tr>
<tr>
<td>35</td>
<td>Jordan</td>
<td>7</td>
</tr>
<tr>
<td>36</td>
<td>Yemen</td>
<td>24</td>
</tr>
<tr>
<td>37</td>
<td>Israel</td>
<td>8</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>91</strong></td>
<td></td>
</tr>
</tbody>
</table>

We continue to add new and existing distributors into the “contributing to revenue” category. Canada coming on-line soon and many other countries.
Growth Driven by Direct, Distributor, Partner Sales

Theoretical Revenue Growth Based on Layering*

- Africa
- South America
- North America
- Asia
- Australia
- Middle East
- Partner 3
- Partner 2
- Partner 1
- Current Distributors
- Direct

* This graph is provided only to demonstrate the concept of revenue layering. It does NOT represent revenue forecasts or guidance.
Quarterly Product Sales

Fourth Consecutive quarter of product sales growth
Third consecutive quarter of record sales
Key Catalyst #2:

Drive Clinical Data to Support CytoSorb As Standard of Care
Robust Clinical Program and Team

Chief Medical Officer

- Sepsis Advisory Board
- Cardiac Surgery Advisory Board
- Trauma Advisory Board

Director of Clinical Operations

- Statistician

Medical Director

- Sr.Manager Clinical Affairs
- Director Scientific Affairs

55+ Investigator Initiated Studies

- Germany Dosing Study
- Additional Sepsis Trials

Publications

REFRESH:
- Cardiac Surgery
- Sepsis
- Trauma

CytoSorbents

International CytoSorb Registry

CytoSorbents
Working to Save Lives Through Blood Purification
Many Published Peer-Reviewed Articles
Refractory Septic Shock

At the 26th Symposium for Intensive Medicine + Critical Care in Bremen, Germany, Dr. Sigrun Friesecke, Senior Intensivist in the Greifswald University Hospital MICU reported on a prospective, single arm study in 22 patients with refractory late-stage septic shock

• Patients had refractory shock despite high doses of vasopressors, respiratory failure requiring mechanical ventilation or ECMO, anuric kidney failure requiring dialysis, and lactate > 8 mmol/L

• A similar population (n=16) receiving standard of care, where shock could not be reversed, also on mechanical ventilation with an initial lactate level of 6.1 ± 4 mmol/L, and 75% requiring renal replacement therapy had a mortality of 100% at 28 days.*

• Results from the CytoSorb Greifswald Study
  • 28-day survival was 41%, a 30-40% absolute improvement over expected (0-10%)
  • Resolution of shock in 68% of patients treated with CytoSorb
  • Reduction of IL-6 from an initial average of 87,000 pg/mL to below 10,000 pg/mL after 24 hours of treatment

CytoSorb Website – A Wealth of Info

Visit us at www.cytosorb.com
3rd International CytoSorb Users Meeting

For more information, visit:
Key Catalyst #3:
Pursue U.S. Regulatory Approval of CytoSorb in Cardiac Surgery
REFRESH I Trial Update
REduction in FREe Hemoglobin

• 40-patient, eight-center study evaluating the safety and efficacy of intra-operative use of CytoSorb® in a heart-lung machine during complex cardiac surgery in elective, non-emergent cardiac surgery > 3 hours
  • Aortic reconstruction, CABG redos, multiple valve replacements, etc

• Goal: Safe reduction of plasma-free hemoglobin and other inflammatory mediators that can cause post-operative complications
REFRESH I Trial Update
REduction in FREe Hemoglobin Trial

• Working with major cardiac surgery centers
  • Baylor College of Medicine and Texas Heart Institute
  • Baystate Medical Center
  • Columbia University
  • Cooper University Hospital
  • University of Kentucky
  • University of Maryland
  • University of Pennsylvania
  • University of Pittsburgh Medical Center

• DSMB analyzed safety data from the first 24 patients and found no safety concerns
• Final 6 patients left to enroll. Expect to complete enrollment soon with top-line results available in Q3 2016
• Pending the successful completion of REFRESH I and agreement with the FDA, the REFRESH 2 trial is expected to start early next year
Key Catalyst #4:

Leverage Pipeline to Establish Strategic Partnerships
Beads Enable a Broad and Valuable Pipeline

Critical Care, High Risk Surgery
Blood Collection & Transfusion
CT Imaging, Interventional Radiology
Drug Overdose, Chemo Removal
Improving Dialysis

CE Mark Approved
Under Development

CytoSorbents
Working to Save Lives Through Blood Purification
*Companies listed here are used simply as examples of companies in these respective verticals. We make no other representations to our relationship with any of these companies.
Fresenius Medical Care Partnership

- Entered into a multi-year partnership with Fresenius, the world’s largest dialysis company, for exclusive distribution of CytoSorb® in critical care in France, Poland, Denmark, Norway, Sweden, and Finland

- CytoSorb® is a key part of Fresenius’ growth strategy in critical care

- Fresenius has committed to annual minimum purchases to maintain exclusivity

- Leveraging Fresenius’ critical care leadership and industry-leading sales force and distribution

- Potential for broader future synergy and expansion

- In May, Fresenius launched CytoSorb® with a 30-person ICU sales force that is also selling Fresenius products
Biocon Strategic Partnership: Creating the Most Comprehensive Treatment for Sepsis

- Biocon is the largest biotechnology company in India
- Significant growth in India with expansion into Sri Lanka
- Expanded partnership to include co-development and funding of small trials
- Creating a separate sales division to focus specifically on CytoSorb
Key Catalyst #5: Increase Investor Awareness
NASDAQ Capital Market Listed

• Clean capital structure with good liquidity for investors
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to reduce deadly uncontrolled inflammation in hospitalized patients around the world, is set to join the Russell Microcap® Index at the conclusion of the Russell indexes annual reconstitution on June 26, 2015, according to a preliminary list of additions posted on June 12, 2015.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, "We are pleased to be included in the Russell Microcap Index, a significant corporate achievement that is expected to increase visibility and exposure of our company and life-saving technology to the broader investment community. This complements our continued institutional investor outreach, where the response has been extremely positive to date."

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $5.7 trillion in assets are benchmarked to the Russell’s U.S. indexes. Russell Indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 1000 and the Russell indexes reconstitution, go to “Recon Central” on the FTSE Russell website.
Increase Institutional Ownership

CytoSorbents (NASDAQ: CTSO)

<table>
<thead>
<tr>
<th>Owner Name</th>
<th>Date</th>
<th>Shares Held</th>
<th>Change (Shares)</th>
<th>Change (%)</th>
<th>Value (in 1,000s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAN GUARD GROUP INC</td>
<td>03/31/2016</td>
<td>532,261</td>
<td>24,198</td>
<td>4.76</td>
<td>2,369</td>
</tr>
<tr>
<td>AMERICAN INTERNATIONAL GROUP INC</td>
<td>03/31/2016</td>
<td>271,045</td>
<td>27,000</td>
<td>11.06</td>
<td>1,206</td>
</tr>
<tr>
<td>GEODE CAPITAL MANAGEMENT, LLC</td>
<td>03/31/2016</td>
<td>125,772</td>
<td>(101)</td>
<td>(0.08)</td>
<td>560</td>
</tr>
<tr>
<td>RAYMOND JAMES &amp; ASSOCIATES</td>
<td>03/31/2016</td>
<td>77,551</td>
<td>77,551</td>
<td>New</td>
<td>345</td>
</tr>
<tr>
<td>SKYLANDS CAPITAL, LLC</td>
<td>03/31/2016</td>
<td>52,500</td>
<td>0</td>
<td>0.00</td>
<td>234</td>
</tr>
<tr>
<td>CALIFORNIA PUBLIC EMPLOYEES</td>
<td>03/31/2016</td>
<td>46,100</td>
<td>0</td>
<td>0.00</td>
<td>205</td>
</tr>
<tr>
<td>RETIREMENT SYSTEM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BLACKROCK FUND ADVISORS</td>
<td>03/31/2016</td>
<td>38,712</td>
<td>(2,884)</td>
<td>(6.93)</td>
<td>172</td>
</tr>
<tr>
<td>SUSQUEHANNA INTERNATIONAL</td>
<td>03/31/2016</td>
<td>37,797</td>
<td>5,628</td>
<td>17.50</td>
<td>168</td>
</tr>
<tr>
<td>GROUP, LLP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BANK OF NEW YORK MELLON CORP</td>
<td>03/31/2016</td>
<td>29,945</td>
<td>11,065</td>
<td>50.60</td>
<td>133</td>
</tr>
<tr>
<td>BLACKROCK INSTITUTIONAL TRUST</td>
<td>03/31/2016</td>
<td>26,460</td>
<td>0</td>
<td>0.00</td>
<td>118</td>
</tr>
<tr>
<td>COMPANY, N.A.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CREDIT SUISSE AG/</td>
<td>03/31/2016</td>
<td>25,527</td>
<td>10,971</td>
<td>75.37</td>
<td>114</td>
</tr>
<tr>
<td>NORTHERN TRUST CORP</td>
<td>03/31/2016</td>
<td>23,709</td>
<td>0</td>
<td>0.00</td>
<td>106</td>
</tr>
<tr>
<td>LADENBURG THALMANN FINANCIAL</td>
<td>03/31/2016</td>
<td>23,600</td>
<td>4,410</td>
<td>23.04</td>
<td>105</td>
</tr>
<tr>
<td>SERVICES INC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLENMEDE TRUST CO NA</td>
<td>03/31/2016</td>
<td>19,008</td>
<td>0</td>
<td>0.00</td>
<td>85</td>
</tr>
<tr>
<td>FORTALEZA ASSET MANAGEMENT INC/</td>
<td>03/31/2016</td>
<td>14,910</td>
<td>0</td>
<td>0.00</td>
<td>66</td>
</tr>
</tbody>
</table>

Source: NASDAQ

5.6% Institutional Ownership (3/31/16)
Increase Investor Coverage

**CytoSorbents Corporation (CTSO)**

CytoSorbents Corporation (CTSO) is a medical device company that develops and commercializes products that improve the efficiency of the human cardio-pulmonary bypass (CPB) system. These products, such as CytoSorb, are designed to reduce the risk of complications associated with CPB and support patient recovery post-surgery. The company's mission is to improve patient outcomes and reduce healthcare costs by offering more effective treatment solutions.

**Maxim Group**

Maxim Group initiated coverage on CytoSorbents Corporation (CTSO) with a Buy rating and a $28.00 price target. The analyst noted the company's potential to expand its product portfolio and enter new markets, which could drive growth.

**Zacks Small-Cap Research**

Zacks Small-Cap Research initiates coverage on CytoSorbents Corporation (CTSO) with a Buy rating and a $12.00 price target. The research highlights the company's potential for long-term growth and the attractive valuation compared to its peers.

**WBB Securities, LLC**

WBB Securities, LLC is initiating coverage on CytoSorbents Corporation (CTSO) with a Speculative Buy rating and a 12-month price target of $13.00. The firm expects the company to benefit from its ongoing clinical trials and the potential market expansion.

**H.C. Wainwright & Co.**

H.C. Wainwright & Co. provides an earnings update and initiates coverage on CytoSorbents Corporation (CTSO) with a Buy rating. The firm notes the company's commitment to research and development and the potential for significant clinical trial results.

**REVIEW OF EARNINGS**

CytoSorbents Corporation (CTSO) has reported earnings, which include a discussion of the company's financial performance and the impact of its products on patient outcomes. The earnings report highlights the company's growth strategies and the potential for future revenue streams.

**Increase Investor Coverage**

The image contains a page from a document discussing the potential benefits of increasing investor coverage for CytoSorbents Corporation (CTSO). The page includes financial data, analyst recommendations, and information on the company's research and development efforts. The text emphasizes the importance of investor coverage in driving the company's success and improving its market position.
Build Momentum in Key Media

CytoSorbents inks deal with Fresenius Medical Care

CytoSorbents Corp (NASDAQ:CTSO) Rebounding on a Stronger Note

CytoSorbents To Advance HemoDefend Towards Commercialization with $1.5 Million Phase II SBIR Contract from NHLBI/NIH

CytoSorbents Files IDE for CytoSorb Cardiac Surgery Trial

CytoSorbents no longer an OTC stock, uplists to Nasdaq

CytoSorbents ink deal with Fresenius Medical Care

Cardiovascular News

FDA News

Microcap Daily

Fierce Medical Devices

Fierce Drug Delivery
CytoSorbents Has Tremendous Potential

CytoSorbents is a hybrid: Combines the greater visibility and lower risk of a medical device company with product sales with the upside potential of biotech

- Massive untapped $20 billion unmet, medical need in critical care
- Generating significant international CytoSorb® sales growth with 60+% gross margins
- Fueling growth through more usage, clinical data, and continued geographic expansion
- Pursuing CytoSorb® FDA approval through our REFRESH I and II cardiac surgery trials
- Expansion of existing strategic partnerships and addition of new partners
- Greater market awareness and financing for success

CytoSorb is helping to save lives throughout the world
Providing Hope in a helpless situation

HELPING PATIENTS SURVIVE CRITICAL ILLNESSES WORLDWIDE

CytoSorbents
Working to Save Lives Through Blood Purification

NASDAQ: CTSO
Dr. Phillip Chan, MD, PhD – CEO
pchan@cytosorbents.com